Enhancing the HemOnc Knowledgebase of Chemotherapy Drugs and Regimens

增强 HemOnc 化疗药物和治疗方案的知识库

基本信息

  • 批准号:
    10333856
  • 负责人:
  • 金额:
    $ 74.8万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-15 至 2027-08-31
  • 项目状态:
    未结题

项目摘要

Project Summary Systemic cancer treatments have transformed the landscape for many patients with cancer, yet are toxic and often given in complicated combinations and protocols. In 2011, we began to build the HemOnc.org website as a free and open resource for hematology and oncology healthcare professionals. HemOnc.org contains granular information on anti-cancer drugs, regimens, and guidelines, and is now the largest resource of its kind. In 2020, there were >250,000 unique visitors and >1,000,000 pageviews from 181 countries. Users are primarily split between clinicians and pharmacists, with utilization by trainees as well as experienced practitioners. Translational researchers also utilize the site as a source of domain knowledge. Beginning in 2017, we formalized the structure of much of the content on HemOnc.org, enabling its transformation into a structured vocabulary, HemOnc. As of January 2021, HemOnc comprises 83,879 concepts across 30 concept classes, and 223,039 relationships across 45 relationship types. Explicit mappings exist between HemOnc and RxNorm, CanMED, SNOMED-CT, OncoTree, and the NCI Thesaurus. Several organizations and projects actively utilize or are evaluating HemOnc, including AACR Project GENIE, the ITCR-funded DeepPhe project, the Variant Interpretation for Cancer Consortium, and cBioPortal. In addition to maintaining the steady growth in content that has taken place over the past nine years, we aim to enhance the HemOnc.org website and HemOnc ontology through the following five specific aims: 1) present interactive ranked regimen graphs on the website; 2) allow for dynamic temporal exploration of regimens, studies, and authors with an interactive Regimen Browser; 3) grow and refine the HemOnc ontology; 4) build structured summaries and narrative synopses for the most important anticancer regimens, including identification of regimens specifically evaluated in underrepresented populations; 5) cultivate a robust user community. This work will be undertaken by an accomplished team of clinicians and translational researchers.
项目摘要 全身性癌症治疗已改变了许多癌症患者的景观,但 有毒,通常以复杂的组合和协议给药。 2011年,我们开始建造 hemonc.org网站是血液学和肿瘤医疗保健的免费开放资源 专业人士。 hemonc.org包含有关抗癌药物,方案和 指南,现在是同类最大的资源。在2020年,有> 250,000的独特 来自181个国家 /地区的访客和> 1,000,000个浏览量。用户主要分配在临床医生之间 和药剂师,以及受训者以及经验丰富的从业人员的利用。翻译 研究人员还利用该网站作为领域知识的来源。从2017年开始,我们 正式化了hemonc.org上许多内容的结构,从而使其转换为 结构化词汇,hemonc。截至2021年1月,HemonC包括83,879个概念 在30个概念类别中,以及45种关系类型的223,039个关系。显式 映射存在于Hemonc和Rxnorm之间,Canmed,Snomed-CT,Oncotree和NCI 词库。几个组织和项目积极利用或正在评估Hemonc, 包括AACR Project Genie,ITCR资助的Deepphe项目,变体解释 癌症联盟和cbioportal。除了保持内容的稳定增长外 在过去的九年中,我们旨在增强hemonc.org网站和 通过以下五个特定目标:1)当前的交互式排名方案 网站上的图形; 2)允许对方案,研究和 具有交互式浏览器的作者; 3)成长和完善Hemonc本体论; 4)构建 最重要的抗癌方案的结构化摘要和叙事摘要, 包括鉴定在代表性不足的人群中专门评估的方案; 5) 培养一个强大的用户社区。这项工作将由一支成熟的团队进行 临床医生和翻译研究人员。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jeremy Lyle Warner其他文献

Evaluating the Accuracy of Artificial Intelligence(AI)-Generated Synopses for Plasma Cell Disorder Treatment Regimens
  • DOI:
    10.1182/blood-2024-208513
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    Aleenah Mohsin;Samuel M. Rubinstein;Rahul Banerjee;Sanjay Mishra;Mary Kwok;Peter Yang;Jeremy Lyle Warner;Andrew J. Cowan
  • 通讯作者:
    Andrew J. Cowan

Jeremy Lyle Warner的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jeremy Lyle Warner', 18)}}的其他基金

Enhancing the HemOnc Knowledgebase of Chemotherapy Drugs and Regimens
增强 HemOnc 化疗药物和治疗方案的知识库
  • 批准号:
    10705015
  • 财政年份:
    2022
  • 资助金额:
    $ 74.8万
  • 项目类别:

相似海外基金

Enhancing the HemOnc Knowledgebase of Chemotherapy Drugs and Regimens
增强 HemOnc 化疗药物和治疗方案的知识库
  • 批准号:
    10705015
  • 财政年份:
    2022
  • 资助金额:
    $ 74.8万
  • 项目类别:
Characterization of TRPC6 to predict and prevent chemotherapy-related heart failure
TRPC6 的表征可预测和预防化疗相关心力衰竭
  • 批准号:
    10705329
  • 财政年份:
    2022
  • 资助金额:
    $ 74.8万
  • 项目类别:
Disparities in the Use of Oral Anticancer Agents in Kidney Cancer
肾癌口服抗癌药物使用的差异
  • 批准号:
    10306983
  • 财政年份:
    2021
  • 资助金额:
    $ 74.8万
  • 项目类别:
Disparities in the Use of Oral Anticancer Agents in Kidney Cancer
肾癌口服抗癌药物使用的差异
  • 批准号:
    10376266
  • 财政年份:
    2021
  • 资助金额:
    $ 74.8万
  • 项目类别:
Disparities in the Use of Oral Anticancer Agents in Kidney Cancer
肾癌口服抗癌药物使用的差异
  • 批准号:
    10545169
  • 财政年份:
    2021
  • 资助金额:
    $ 74.8万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了